Zacks Research Issues Negative Forecast for ACAD Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Analysts at Zacks Research dropped their Q1 2025 earnings per share estimates for ACADIA Pharmaceuticals in a report issued on Tuesday, March 18th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $0.09 per share for the quarter, down from their previous estimate of $0.14. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals' Q4 2025 earnings at $0.19 EPS, FY2025 earnings at $0.68 EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.26 EPS, Q3 2026 earnings at $0.32 EPS, Q4 2026 earnings at $0.33 EPS, FY2026 earnings at $1.01 EPS and FY2027 earnings at $1.37 EPS.

A number of other brokerages have also recently issued reports on ACAD. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, March 8th. Guggenheim lowered ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their target price for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Needham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Cantor Fitzgerald restated an "overweight" rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, HC Wainwright reiterated a "buy" rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Eight analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, ACADIA Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $24.00.

Remove Ads

ACADIA Pharmaceuticals Trading Up 2.6 %

Shares of NASDAQ:ACAD traded up $0.44 during midday trading on Thursday, hitting $17.23. 1,065,952 shares of the stock were exchanged, compared to its average volume of 1,768,087. ACADIA Pharmaceuticals has a twelve month low of $14.15 and a twelve month high of $20.68. The company has a 50 day moving average price of $18.36 and a 200-day moving average price of $17.02. The stock has a market cap of $2.87 billion, a P/E ratio of 22.09 and a beta of 0.43.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ACAD. Summit Investment Advisors Inc. raised its holdings in shares of ACADIA Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 12,519 shares of the biopharmaceutical company's stock valued at $230,000 after buying an additional 795 shares during the period. Quest Partners LLC raised its stake in shares of ACADIA Pharmaceuticals by 42.3% during the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 1,047 shares during the period. Arete Wealth Advisors LLC lifted its position in shares of ACADIA Pharmaceuticals by 15.9% during the fourth quarter. Arete Wealth Advisors LLC now owns 13,700 shares of the biopharmaceutical company's stock worth $251,000 after purchasing an additional 1,875 shares in the last quarter. KBC Group NV boosted its stake in shares of ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 2,044 shares during the period. Finally, Virtus Fund Advisers LLC purchased a new stake in ACADIA Pharmaceuticals during the 4th quarter worth $39,000. Hedge funds and other institutional investors own 96.71% of the company's stock.

Insider Buying and Selling

In related news, Director Elizabeth A. Garofalo sold 4,919 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the sale, the director now directly owns 17,595 shares of the company's stock, valued at approximately $320,756.85. This represents a 21.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 6,167 shares of company stock valued at $114,583. 28.30% of the stock is currently owned by corporate insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.